We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Reasons to Add West Pharmaceutical (WST) to Your Portfolio Now
Read MoreHide Full Article
West Pharmaceutical Services, Inc. (WST - Free Report) is well poised for growth, backed by the robust Proprietary Products segment and sustained strength in research and development (R&D). However, foreign exchange volatility is a concern.
Shares of this Zacks Rank #1 (Strong Buy) company have risen 63% year to date compared with the industry's 15% growth. The S&P 500 Index has increased 18.5% in the same period.
West Pharmaceutical, with a market capitalization of $28.59 billion, is a leading global manufacturer, engaged in the design and production of technologically advanced, high-quality, integrated containment and delivery systems for injectable drugs and healthcare products. Its earnings are anticipated to improve 13.3% in 2024. The company delivered a trailing four-quarter average earnings surprise of 13.61%.
Image Source: Zacks Investment Research
Key Catalysts
The Proprietary Products business continues to exhibit sustained strength and is an important contributor to WST's top line. This segment's customers primarily comprise several of the major biologic, generic and pharmaceutical drug companies globally that incorporate components and other offerings in their injectable products.
Sales improved 2.3% organically in the first quarter of 2023. High-value products (components and devices) accounted for more than 70% of segment sales and delivered mid-single digit organic sales growth.
Growth in demand, especially from biologic customers, and strong performances in Generics and Pharma market units, buoy optimism. West Pharmaceutical also continues to expand high-value product manufacturing capacity for supporting rising customer demand from recent launches and anticipated drug programs in the coming years.
Robust organic growth of Proprietary Products’ Generics and Pharma market units is another quarterly highlight.
The company maintains its research-scale production facilities and laboratories for creating new products. It also provides contract engineering design and development services to help customers with new product developments.
WST continues to pursue innovative strategic platforms in prefillable syringes, injectable containers, advanced injections, and safety and administration systems. In the first quarter, the company's R&D expenses increased 17.1% from the prior-year period’s level.
West Pharmaceutical remains committed to seeking innovative opportunities for the acquisition, licensing, partnering or development of products, services and technologies. The company is focused on its objective of connecting dots throughout science and technology for potential value creation.
Factors Hurting the Stock
The growing exposure to international markets makes WST susceptible to adverse foreign exchange volatility. Unfavorable fluctuations in currency exchange rates can affect WST’s international sales. On its first-quarter 2023 earnings call, the company projected forex headwind on revenues of $15 million for 2023.
Moreover, the constant fall in the Contract-Manufactured Products segment is concerning. Lower demand for COVID-related products is also worrying. Contraction in gross and operating margins does not bode well. West Pharmaceutical’s pandemic-related sales are also likely to experience a downtrend in the rest of 2023, thereby hurting Proprietary Products’ revenue growth.
Estimates Trend
The company has been witnessing an upward estimate revision trend in 2023. In the past 60 days, the Zacks Consensus Estimate for earnings has improved 4.5% to $7.69 per share.
The consensus estimate for 2023 revenues is pegged at $2.98 billion, indicating a 3.1% increase from the 2022 level.
Hologic has an estimated earnings growth rate of 4.1% for fiscal 2024. Its earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 27.32%.
HOLX’s shares have risen 5.6% year to date compared with the industry’s 8.4% growth.
Alcon has an estimated long-term growth rate of 14.9%. Its earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 8.85%.
ALC’s shares have rallied 22.8% year to date compared with the industry’s 8.4% growth.
DexCom has an estimated long-term growth rate of 40.4%. Its earnings surpassed estimates in three of the trailing four quarters and met the same once, delivering an average surprise of 15.19%.
DXCM’s shares have risen 18% year to date compared with the industry’s 8.4% growth.
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Shutterstock
Reasons to Add West Pharmaceutical (WST) to Your Portfolio Now
West Pharmaceutical Services, Inc. (WST - Free Report) is well poised for growth, backed by the robust Proprietary Products segment and sustained strength in research and development (R&D). However, foreign exchange volatility is a concern.
Shares of this Zacks Rank #1 (Strong Buy) company have risen 63% year to date compared with the industry's 15% growth. The S&P 500 Index has increased 18.5% in the same period.
West Pharmaceutical, with a market capitalization of $28.59 billion, is a leading global manufacturer, engaged in the design and production of technologically advanced, high-quality, integrated containment and delivery systems for injectable drugs and healthcare products. Its earnings are anticipated to improve 13.3% in 2024. The company delivered a trailing four-quarter average earnings surprise of 13.61%.
Image Source: Zacks Investment Research
Key Catalysts
The Proprietary Products business continues to exhibit sustained strength and is an important contributor to WST's top line. This segment's customers primarily comprise several of the major biologic, generic and pharmaceutical drug companies globally that incorporate components and other offerings in their injectable products.
Sales improved 2.3% organically in the first quarter of 2023. High-value products (components and devices) accounted for more than 70% of segment sales and delivered mid-single digit organic sales growth.
Growth in demand, especially from biologic customers, and strong performances in Generics and Pharma market units, buoy optimism. West Pharmaceutical also continues to expand high-value product manufacturing capacity for supporting rising customer demand from recent launches and anticipated drug programs in the coming years.
Robust organic growth of Proprietary Products’ Generics and Pharma market units is another quarterly highlight.
The company maintains its research-scale production facilities and laboratories for creating new products. It also provides contract engineering design and development services to help customers with new product developments.
WST continues to pursue innovative strategic platforms in prefillable syringes, injectable containers, advanced injections, and safety and administration systems. In the first quarter, the company's R&D expenses increased 17.1% from the prior-year period’s level.
West Pharmaceutical remains committed to seeking innovative opportunities for the acquisition, licensing, partnering or development of products, services and technologies. The company is focused on its objective of connecting dots throughout science and technology for potential value creation.
Factors Hurting the Stock
The growing exposure to international markets makes WST susceptible to adverse foreign exchange volatility. Unfavorable fluctuations in currency exchange rates can affect WST’s international sales. On its first-quarter 2023 earnings call, the company projected forex headwind on revenues of $15 million for 2023.
Moreover, the constant fall in the Contract-Manufactured Products segment is concerning. Lower demand for COVID-related products is also worrying. Contraction in gross and operating margins does not bode well. West Pharmaceutical’s pandemic-related sales are also likely to experience a downtrend in the rest of 2023, thereby hurting Proprietary Products’ revenue growth.
Estimates Trend
The company has been witnessing an upward estimate revision trend in 2023. In the past 60 days, the Zacks Consensus Estimate for earnings has improved 4.5% to $7.69 per share.
The consensus estimate for 2023 revenues is pegged at $2.98 billion, indicating a 3.1% increase from the 2022 level.
West Pharmaceutical Services, Inc. Price
West Pharmaceutical Services, Inc. price | West Pharmaceutical Services, Inc. Quote
Other Stocks to Consider
Some other top-ranked stocks from the broader medical space are Hologic (HOLX - Free Report) , Alcon (ALC - Free Report) and DexCom (DXCM - Free Report) . While Hologic sports a Zacks Rank #1, both Alcon and DexCom carry a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Hologic has an estimated earnings growth rate of 4.1% for fiscal 2024. Its earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 27.32%.
HOLX’s shares have risen 5.6% year to date compared with the industry’s 8.4% growth.
Alcon has an estimated long-term growth rate of 14.9%. Its earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 8.85%.
ALC’s shares have rallied 22.8% year to date compared with the industry’s 8.4% growth.
DexCom has an estimated long-term growth rate of 40.4%. Its earnings surpassed estimates in three of the trailing four quarters and met the same once, delivering an average surprise of 15.19%.
DXCM’s shares have risen 18% year to date compared with the industry’s 8.4% growth.